Innovent Biologics
2000 Alameda de las Pulgas, suite 120
San Mateo
CA
94403
United States
Website: https://www.innoventbio.com/
220 articles about Innovent Biologics
-
Innovent Announces Inclusion in the China National Reimbursement Drug List (NRDL) of TYVYT in Two New Indications, Olverembatinib for the First Listing, BYVASDA, HALPRYZA and SULINNO in Multiple New Indications
1/18/2023
Innovent Biologics, Inc. today announced that, five products (including new indications) of the company have been included in the updated National Reimbursement Drug List (2022 Version) ("NRDL").
-
Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (DREAMS-2) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes
1/10/2023
Innovent Biologics, Inc. (Innovent) (HKEX: 01801) today announced that the first participant has been successfully dosed in a multicenter, randomized, dulaglutide-controlled phase 3 clinical trial (DREAMS-2) of mazdutide (Innovent R&D Code: IBI362), a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese patients with type 2 diabetes.
-
Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (DREAMS-1) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes
1/9/2023
Innovent Biologics, Inc. (Innovent) (HKEX: 01801) today announced that the first participant has been successfully dosed in a multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trial (DREAMS-1) of mazdutide (Innovent R&D Code: IBI362), a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese patients with type 2 diabetes.
-
Innovent Announces the National Medical Products Administration in China Has Accepted and Granted Priority Review Designation to the NDA for Parsaclisib (PI3Kδ inhibitor) for the Treatment of Relapsed or Refractory Follicular Lymphoma
1/6/2023
Innovent Biologics, Inc. announces that the New Drug Application for parsaclisib for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two previous systemic therapies has been accepted for review by China's Center for Drug Evaluation of the National Medical Products Administration and granted Priority Review designation.
-
Innovent Announces NMPA's Breakthrough Therapy Designation for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Previous Treated Advanced Non-small Cell Lung Cancer
1/5/2023
Innovent Biologics, Inc. announced that the Center for Drug Evaluation of China's National Medical Products Administration has granted Breakthrough Therapy Designation for IBI351 for the treatment of advanced non-small cell lung cancer patients with KRASG12C mutation that have received at least one prior line of systemic therapy.
-
Innovent to Present at 41st Annual J.P. Morgan Healthcare Conference
1/4/2023
Innovent Biologics, Inc. announced that the Company will participate in the 41st Annual J.P. Morgan Healthcare Conference held on January 9-12, 2023 in San Francisco and Dr. De-Chao Michael Yu, Founder, Chairman and CEO of Innovent will present on Wednesday, January 11, 2023 at 10:00am Pacific Standard Time.
-
Innovent and LG Chem Announce Strategic Collaboration for Tigulixostat, a Novel Non-Purine Xanthine Oxidase Inhibitor for the Treatment of Gout Disease
12/15/2022
Innovent Biologics and LG Chem Life Sciences announced that the two parties have entered into a strategic collaboration and license agreement regarding LG Chem's Tigulixostat, a late-stage novel non-purine xanthine oxidase inhibitor for the chronic management of hyperuricemia in patients with gout disease.
-
Innovent Presents Phase 1b Clinical Data of IBI188 (Anti-CD47 Monoclonal Antibody) at the 2022 American Society of Hematology Annual Meeting
12/11/2022
Innovent Biologics, Inc. announced that clinical data of IBI188 as first-line treatment in newly diagnosed higher risk myelodysplastic syndrome is presented at the 2022 American Society of Hematology Annual Meeting, held Dec 10-13, 2022.
-
Innovent Presents Phase Ib Clinical Data Update of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 European Society For Medical Oncology Immuno-Oncology Congress
12/9/2022
Innovent Biologics, Inc. announced that updated clinical data of IBI110 in advanced squamous non-small cell lung cancer is presented at the 2022 European Society for Medical Oncology Immuno-Oncology Congress, held Dec 7-9, 2022.
-
Innovent Presents Phase Ib Clinical Data of IBI939 (Anti-TIGIT Monoclonal Antibody) in Previously Untreated PD-L1-selected NSCLC at the 2022 European Society For Medical Oncology Immuno-Oncology Congress
12/9/2022
Innovent Biologics, Inc. announced that clinical data of IBI939 is presented at the 2022 European Society for Medical Oncology Immuno-Oncology Congress, Dec 7-9, 2022.
-
Innovent and UNION Therapeutics Announce First Subject Dosed in a Chinese Clinical Phase I Study of the Novel PDE4 Inhibitor Orismilast (IBI353)
12/5/2022
Innovent Biologics, Inc. and UNION therapeutics A/S announced that the first Chinese healthy volunteer has been successfully dosed in the Phase I study of orismilast, a potential best-in-class PDE4 inhibitor in global clinical Phase II stage.
-
Innovent Announced Clinical Data of Multiple Trials Will be Presented at the 2022 ESMO-IO and ASH Annual Meetings
11/28/2022
Innovent Biologics, Inc. announced that clinical data from multiple trials in relation to TYVYT®, olverembatinib, IBI188, IBI110 and IBI939 will be presented at the upcoming international medical conferences.
-
Innovent Presents Clinical Data of Phase Ia Study for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Solid Tumors at the 2022 Chinese Society of Clinical Oncology (CSCO) Annual Meeting
11/14/2022
Innovent Biologics, Inc. presented the updated results of IBI351 from a phase Ia clinical trial at the 2022 Chinese Society of Clinical Oncology Annual Meeting.
-
Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (GLORY-1) of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity
11/14/2022
Innovent Biologics, Inc. (Innovent) (HKEX: 01801) today announced that the first participant has been successfully dosed in a phase 3 clinical trial (GLORY-1) of mazdutide (Innovent R&D Code: IBI362), a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese adults with overweight or obesity.
-
Innovent Releases Results of a Phase 3 Clinical Study of Tafolecimab(IBI306)in Chinese Patients with non- Familial Hypercholesterolemia at the American Heart Association (AHA) Scirntific Sessions 2022
11/7/2022
Innovent Biologics, Inc. announces that the results of a phase 3 clinical study of tafolecimab, a recombinant fully human anti-PCSK-9 monoclonal antibody, in Chinese patients with non-familial hypercholesterolemia were presented at the American Heart Association Scientific Sessions 2022 as an e-poster.
-
Innovent Announces First Patient Dosing in Australia in Phase I Study of IBI343 (Recombinant anti-Claudin18.2 Monoclonal Antibody-drug Conjugate) in Patients with Advanced Solid Tumors
10/31/2022
Innovent Biologics, Inc. announced that the first patient was dosed in Australia for its proprietary anti-Claudin18.2 monoclonal antibody-drug conjugate in Phase I clinical trial for the treatment of patients with advanced solid tumors.
-
Innovent Announces Phase Ib Results of Higher-dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalMedicine
10/17/2022
Innovent Biologics, Inc. announced that results of higher-dose cohorts in a phase 1b study of mazdutide (IBI362), a glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist, in Chinese participants with overweight or obesity have been published online in eClinicalMedicine
-
The China NMPA Approves Selpercatinib for the Treatment of Patients with RET-driven Lung and Thyroid Cancers
10/10/2022
Innovent Biologics, Inc. is pleased to see that the NMPA of China has approved the NDA for selpercatinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with a rearranged during transfection gene fusion, adult and pediatric patients 12 years of age and older with advanced or metastatic medullary thyroid cancer with a RET mutation who require systemic therapy.
-
The China NMPA Approved CYRAMZA® (ramucirumab) for the Treatment in Patients with Hepatocellular Carcinoma
10/10/2022
Innovent Biologics, Inc. is pleased to see that the National Medical Products Administration of China has approved the supplemental New Drug Application for CYRAMZA® in patients with hepatocellular carcinoma, who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib.
-
Innovent's Sintilimab plus Chemotherapy Demonstrated PFS Benefit in Patients with EGFR-mutated Non-Squamous Non-Small Cell Lung Cancer in the Second Interim Analysis Results of the ORIENT-31 Study
9/7/2022
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801) announced second interim analysis results of the randomized, double-blinded, multi-center Phase 3 ORIENT-31 study (NCT03802240) conducted in China evaluating sintilimab with or without anti-VEGF antibody therapy.